Ariceum Therapeutics

What Ariceum Therapeutics does

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company founded in 2021 and headquartered in Berlin, Germany, developing targeted radiotherapeutics and diagnostics for neuroendocrine tumors and other aggressive, hard-to-treat cancers. The company's core technology centers on proprietary somatostatin receptor 2 (SSTR2) antagonists, with its lead asset satoreotide (SSO110/SSO120) functioning as a first-in-class theranostic pair radiolabeled with Lutetium-177 for therapy and Gallium-68 for imaging. The pipeline was materially expanded through the June 2023 acquisition of Theragnostics, which added a patented Ga-68 radiopharmaceutical production kit (licensed to Novartis for LOCAMETZ), an Iodine-123-labeled PARP inhibitor (ATT001) in clinical development for glioblastoma, and NEPHROSCAN, an FDA-approved renal imaging diagnostic distributed via GE Healthcare. The lead alpha-emitter program 225Ac-SSO110 received FDA Orphan Drug Designation in February 2025, with a Phase 1/2 trial (SANTANA-225) initiating in November 2025.

The company operates an enterprise field sales model executed through clinical trial sites, hospital cancer centers, and strategic distribution partnerships across Germany, Switzerland, Australia, the UK, and the USA, with isotope supply secured through a multi-isotope agreement with Nusano and a strategic research collaboration with UCB providing access to an mRNA-display peptide discovery platform. Ariceum has dosed over 100 patients with satoreotide and reported a 94.7% disease control rate in its Phase I/II neuroendocrine tumor trial. Revenue mechanics are pre-commercial today, with future revenue expected from a mix of direct product sales (pending regulatory approval), licensing royalties (e.g., Novartis LOCAMETZ), milestone payments, and partnership agreements; the company is privately held with EUR 47.75M in total Series A funding from HealthCap, EQT Life Sciences, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital, and operates with 11-50 employees.

Name

Ariceum Therapeutics

Legal name

Ariceum Therapeutics GmbH

Website

https://ariceum-therapeutics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing first-in-class SSTR2 antagonists (satoreotide) for diagnosis and treatment of neuroendocrine tumors and aggressive cancers, with operations across Germany, Switzerland, Australia, UK, and USA.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Targeted Radiotherapy

NAICS

Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industries

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

Keywords

• Targeted radiopharmaceuticals
• Radioligand therapy
• Cancer theranostics
• Neuroendocrine tumor treatment
• Clinical stage oncology

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Radiopharmaceutical Drug Development and Commercialization: As a clinical-stage company, Ariceum is focused on developing and commercializing its pipeline of targeted radiotherapeutics. Revenue will be generated through product sales upon regulatory approval, as well as potential licensing agreements and partnerships with larger pharmaceutical companies.
2. Licensing and Partnership Revenue: The company generates licensing revenue through technology licensing agreements, such as the Ga-68 kit technology licensed to Novartis for LOCAMETZ, and potential future co-development partnerships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing targeted systemic radiotherapy (STR) products that combine diagnostic imaging and targeted radiotherapy to visualize and treat neuroendocrine tumors and other aggressive cancers. Its lead programs include the SSTR2 antagonist satoreotide (Lu-177/Ga-68 theranostic pair), the alpha-emitter 225Ac-SSO110, the PARP inhibitor Auger therapy 123I-ATT001, and the FDA-approved renal imaging diagnostic NEPHROSCAN distributed via GE Healthcare.

Differentiator

Problem solved

Functional benefit

Brands

• NephroScan: FDA-approved diagnostic product for renal parenchymal disorders, partnered with GE Healthcare.

Products and services

• Satoreotide (SSO110/SSO120) - 177Lu-Satoreotide / 68Ga-Satoreotide First-in-class and best-in-class somatostatin receptor 2 (SSTR2) antagonist radiolabeled with Lutetium-177 for therapy and Gallium-68 for imaging, functioning as a theranostic pair for diagnosis and treatment of neuroendocrine tumors and SSTR2-positive cancers. Being evaluated for neuroendocrine tumors, ES-SCLC, and Merkel Cell Carcinoma. Over 100 patients dosed across early clinical trials.
• 225Ac-SSO110 (Actinium-225 labeled Satoreotide) First SSTR2 antagonist radioligand therapy in clinical development using Actinium-225 alpha radiation, for targeted alpha therapy of extensive-stage small cell lung cancer (ES-SCLC) and Merkel Cell Carcinoma (MCC). Delivers high linear energy transfer alpha particles directly to SSTR2-expressing tumor cells.
• ATT001 (123I-ATT001) - Iodine-123 labeled PARP Inhibitor Iodine-123 radiolabeled PARP inhibitor for Auger electron therapy, delivering targeted subcellular radiotherapy to cancer cells expressing PARP enzyme while sparing healthy tissue. In clinical development for recurrent glioblastoma and other solid tumors.
• NEPHROSCAN FDA-approved diagnostic radiopharmaceutical product for renal scintigraphic imaging used by nuclear medicine and radiology departments for diagnosis of renal parenchymal disorders. Currently commercialized and distributed in the United States via GE Healthcare.
• Gallium-68 (Ga-68) Radiopharmaceutical Production Kit Single-vial, single-step Ga-68 kit technology enabling production of multiple doses of Ga-68 radiopharmaceuticals. Licensed to Novartis for the LOCAMETZ PSMA kit; serves as a platform for generating diagnostic imaging agents.

Quantifiable outcome

• 94.7% disease control rate in neuroendocrine tumor patients (Phase I/II trial, 38 evaluable patients)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• NusanocoreTechnology or Integration · 14 October 2025Multi-isotope supply agreement providing Ariceum access to Nusano-produced radioisotopes including actinium-225 (Ac-225) and lutetium-177 (Lu-177) to support the company's radiotherapeutic pipeline including 225Ac-SSO110 currently in Phase 1/2 trials for small cell lung cancer and Merkel Cell Carcinoma.
• Eurofins CDMOcoreImplementation/ SI/ Consulting Partner · 26 June 2023Strategic partnership where Eurofins CDMO provides Clinical Trial Supply services including Qualified Person release of Drug Substance into Europe, storage, cold chain management, packaging, and delivery of Drug Product to investigational sites for Ariceum's Phase I/II clinical studies.
• GE HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 June 2023Partnership for NEPHROSCAN, an FDA-approved diagnostic product for renal scintigraphic imaging. GE Healthcare distributes NEPHROSCAN in the United States through their radiopharmacy network.
• UCBflagshipStrategic or Co-development Partner · 11 May 2023Exclusive strategic research collaboration to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases. UCB provides access to its mRNA-display technology platform ExtremeDiversity for peptide discovery, while Ariceum provides radiopharmaceutical and labeling expertise.
• GenesisCarecoreStrategic or Co-development PartnerClinical trial partnership for Phase Ib study of satoreotide in extensive-stage small cell lung cancer at the GenesisCare Murdoch Theranostics and Molecular Imaging Centre in Perth, Australia.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Novartis: Pharmaceutical leader with LUTATHERA (SSTR2 agonist, direct competitor to satoreotide) and PLUVICTO (PSMA-targeted RLT). Validates the radiopharmaceutical market opportunity and licenses Ariceum's Ga-68 kit technology for LOCAMETZ.
• Bayer: Diversified pharma with established radiopharmaceutical franchise (Xofigo/radium-223) and active investments in actinium-225 production and next-generation targeted radionuclide therapies, overlapping with Ariceum's therapeutic pipeline.
• Ipsen: Specialty pharma that originally developed satoreotide before divesting rights to Ariceum in 2021. Remains a shareholder and is a broad oncology incumbent with overlapping interest in neuroendocrine tumor treatments.

Direct peers

• Lantheus Holdings: Radiopharmaceutical company with PYLARIFY (Piflufolastat F-18), a PSMA-targeted PET imaging agent. Direct comparable in the radiopharmaceutical oncology imaging and therapy space, particularly for prostate cancer diagnostics.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing Illuccix (Ga-68 PSMA-11) for prostate cancer imaging. Direct competitor in Ga-68 PSMA imaging space and broader theranostic oncology strategy.
• ITM Isotope Technologies: Munich-based radiopharmaceutical company developing targeted radionuclide therapies for various solid tumors. Closely comparable in European radiopharmaceutical development, particularly in Lu-177 and other therapeutic isotopes.
• Fusion Pharmaceuticals: Alpha-emitter radiopharmaceutical company developing Actinium-225 targeted therapies for solid tumors (acquired by AstraZeneca in 2024). Highly comparable to Ariceum's 225Ac-SSO110 alpha-therapy approach and target indications.
• POINT Biopharma: Clinical-stage radiopharmaceutical company developing PNT2002 (Lu-177 PSMA) and PNT2003 (Lu-177 DOTATATE) for prostate and neuroendocrine cancers (acquired by Eli Lilly in 2023). Direct comparable in Lu-177-based RLT development.
• RayzeBio: Actinium-225-based radiopharmaceutical company developing alpha-emitter therapies for solid tumors (acquired by Bristol-Myers Squibb in 2024). Highly comparable alpha-emitter strategy and therapeutic radionuclide development approach.

Emerging players

• Aktis Oncology: Clinical-stage radiopharmaceutical company developing targeted alpha therapies for solid tumors. Emerging peer with overlapping alpha-emitter approach and similar early-stage clinical positioning to Ariceum.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ariceum-therapeutics
• Xx.com/Ariceum_Tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ariceum Therapeutics